Paul C. Lorigan
University of Manchester
2 papers in the Anchorcite directory, published between 2010 and 2015, cited 21,435 times in total.
ORCID profileResearch topics
- Cancer Immunotherapy and Biomarkers · 2 papers
- Cutaneous Melanoma Detection and Management · 2 papers
- Immunotherapy and Immune Responses · 1 paper
- Melanoma and MAPK Pathways · 1 paper
Frequent co-authors
- Caroline Robert · 2 papers
- Frank Stephen Hodi · 1 paper
- Steven J O'Day · 1 paper
- David F. McDermott · 1 paper
- Robert W. Weber · 1 paper
- Jeffrey Alan Sosman · 1 paper
- John B.A.G. Haanen · 1 paper
- Rene C. Gonzalez · 1 paper
Papers
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine · 2010 · 15,401 citations
BACKGROUND: An improvement in overall survival among patients with metastatic melanoma has been an elusive goal. In this phase 3 study, ipilimumab--which blocks cytotoxic T-lymphocyte-associated antigen 4 to potentiate an antitumor T-cell response--administered with or without a glycoprotein 100 (gp100)…
- Pembrolizumab versus Ipilimumab in Advanced MelanomaNew England Journal of Medicine · 2015 · 6,034 citations
BACKGROUND: The immune checkpoint inhibitor ipilimumab is the standard-of-care treatment for patients with advanced melanoma. Pembrolizumab inhibits the programmed cell death 1 (PD-1) immune checkpoint and has antitumor activity in patients with advanced melanoma. METHODS: In this randomized, controlled, phase…
Metadata from OpenAlex (CC0).